FSD Pharma is taking a unique approach to deliver “Total Brain Health” to patients in need. Our mission is to treat the millions of people suffering from diseases by bringing innovative therapies to market. Through our wholly-owned subsidiary, Lucid Psycheceuticals, we have the exclusive worldwide rights to patented CNS compounds with the potential to treat progressive Multiple Sclerosis (“MS”). Additionally, FSD is developing a unique psychedelic-based therapeutic aimed to address a multibillion-dollar mental health market.

Recent News

Get the atai
Investor’s Kit now.


Market Cap